JPH06509072A - 化学療法により誘発される脱毛の予防および治療法 - Google Patents
化学療法により誘発される脱毛の予防および治療法Info
- Publication number
- JPH06509072A JPH06509072A JP5501589A JP50158992A JPH06509072A JP H06509072 A JPH06509072 A JP H06509072A JP 5501589 A JP5501589 A JP 5501589A JP 50158992 A JP50158992 A JP 50158992A JP H06509072 A JPH06509072 A JP H06509072A
- Authority
- JP
- Japan
- Prior art keywords
- rats
- hair loss
- growth factor
- vitamin
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims description 90
- 230000003676 hair loss Effects 0.000 title claims description 84
- 208000024963 hair loss Diseases 0.000 title claims description 82
- 238000002512 chemotherapy Methods 0.000 title claims description 21
- 238000011282 treatment Methods 0.000 title description 21
- 230000002265 prevention Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 42
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 35
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 30
- 239000011647 vitamin D3 Substances 0.000 claims description 30
- 229940021056 vitamin d3 Drugs 0.000 claims description 30
- 235000005282 vitamin D3 Nutrition 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 24
- 239000003102 growth factor Substances 0.000 claims description 23
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 19
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 18
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 18
- 229940116977 epidermal growth factor Drugs 0.000 claims description 18
- 229960005084 calcitriol Drugs 0.000 claims description 17
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 10
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 10
- 230000003779 hair growth Effects 0.000 claims description 10
- 239000002207 metabolite Substances 0.000 claims description 10
- 230000022131 cell cycle Effects 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- 229940044683 chemotherapy drug Drugs 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 238000000554 physical therapy Methods 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000001603 reducing effect Effects 0.000 claims 4
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003328 fibroblastic effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 102
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 238000002474 experimental method Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 28
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 14
- 230000002354 daily effect Effects 0.000 description 13
- 229940009456 adriamycin Drugs 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 229960005420 etoposide Drugs 0.000 description 12
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 11
- 210000003128 head Anatomy 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 229940090044 injection Drugs 0.000 description 8
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 7
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 7
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 7
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 6
- 229940126864 fibroblast growth factor Drugs 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 235000019166 vitamin D Nutrition 0.000 description 6
- 239000011710 vitamin D Substances 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- 229940046008 vitamin d Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940100613 topical solution Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- NEJYHHVQXBABIQ-WCTWPDOZSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NEJYHHVQXBABIQ-WCTWPDOZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000238860 Chrysiogenetes <class> Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 101150111329 ACE-1 gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002922 epistatic effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940124563 hair growth stimulant Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- -1 vitamin D3 Vitamin Chemical class 0.000 description 1
- 239000005544 vitamin D3 metabolite Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72250091A | 1991-06-28 | 1991-06-28 | |
| US722,500 | 1991-06-28 | ||
| US78678891A | 1991-11-01 | 1991-11-01 | |
| US786,788 | 1991-11-01 | ||
| US81041291A | 1991-12-20 | 1991-12-20 | |
| US810,412 | 1991-12-20 | ||
| PCT/US1992/005241 WO1993000079A1 (en) | 1991-06-28 | 1992-06-26 | Method of preventing and treating chemotherapy-induced alopecia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06509072A true JPH06509072A (ja) | 1994-10-13 |
Family
ID=27419035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5501589A Pending JPH06509072A (ja) | 1991-06-28 | 1992-06-26 | 化学療法により誘発される脱毛の予防および治療法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0591378B1 (en, 2012) |
| JP (1) | JPH06509072A (en, 2012) |
| AT (1) | ATE178206T1 (en, 2012) |
| AU (1) | AU667675B2 (en, 2012) |
| CA (1) | CA2112496A1 (en, 2012) |
| CZ (1) | CZ280874B6 (en, 2012) |
| DE (1) | DE69228814T2 (en, 2012) |
| HU (1) | HUT66153A (en, 2012) |
| IE (1) | IE922088A1 (en, 2012) |
| IL (1) | IL102344A (en, 2012) |
| PH (1) | PH31673A (en, 2012) |
| PT (1) | PT100638B (en, 2012) |
| SK (1) | SK279673B6 (en, 2012) |
| TW (1) | TW272128B (en, 2012) |
| WO (1) | WO1993000079A1 (en, 2012) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510652A (ja) * | 1998-04-08 | 2002-04-09 | アボット・ラボラトリーズ | 共溶媒処方物 |
| JP2013501790A (ja) * | 2009-08-14 | 2013-01-17 | バーグ バイオシステムズ，エルエルシー | 脱毛症を治療するためのビタミンｄ３およびその類似体 |
| JP2015174854A (ja) * | 2014-03-17 | 2015-10-05 | 学校法人慶應義塾 | まつ毛の成長を伸展するための組成物 |
| WO2016056644A1 (ja) * | 2014-10-09 | 2016-04-14 | 株式会社メディプロデュース | まつ毛用洗浄剤 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756094A (en) * | 1991-03-27 | 1998-05-26 | Trustees Of The University Of Pennsylvania | Methods for stimulating follicular growth |
| JPH10279501A (ja) * | 1997-02-10 | 1998-10-20 | Rohto Pharmaceut Co Ltd | 育毛剤 |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| FR2778558B1 (fr) * | 1998-05-12 | 2001-02-16 | Oreal | Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute |
| AUPP489798A0 (en) * | 1998-07-28 | 1998-08-20 | Mediko Pty Ltd | Hair growth/maintenance compositions and methods |
| WO2002030430A1 (en) * | 2000-10-06 | 2002-04-18 | Abbott Laboratories | Use of vitamin d2 compounds for alopecia |
| US20030095937A1 (en) * | 2001-10-02 | 2003-05-22 | Koeffler H. Philip | Method for stimulating hair growth by administering vitamin D analogs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| US5102870A (en) * | 1989-04-14 | 1992-04-07 | Schering Ag | Treatment and prevention of oral mucositis with growth factors |
-
1992
- 1992-06-26 EP EP92914032A patent/EP0591378B1/en not_active Expired - Lifetime
- 1992-06-26 JP JP5501589A patent/JPH06509072A/ja active Pending
- 1992-06-26 AU AU22405/92A patent/AU667675B2/en not_active Ceased
- 1992-06-26 CA CA002112496A patent/CA2112496A1/en not_active Abandoned
- 1992-06-26 WO PCT/US1992/005241 patent/WO1993000079A1/en active IP Right Grant
- 1992-06-26 AT AT92914032T patent/ATE178206T1/de not_active IP Right Cessation
- 1992-06-26 DE DE69228814T patent/DE69228814T2/de not_active Expired - Fee Related
- 1992-06-26 SK SK1490-93A patent/SK279673B6/sk unknown
- 1992-06-26 HU HU9303753A patent/HUT66153A/hu unknown
- 1992-06-26 CZ CS932892A patent/CZ280874B6/cs unknown
- 1992-06-26 PT PT100638A patent/PT100638B/pt not_active IP Right Cessation
- 1992-06-28 IL IL102344A patent/IL102344A/en not_active IP Right Cessation
- 1992-06-29 PH PH44589A patent/PH31673A/en unknown
- 1992-07-01 IE IE208892A patent/IE922088A1/en not_active Application Discontinuation
- 1992-09-19 TW TW081107417A patent/TW272128B/zh active
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510652A (ja) * | 1998-04-08 | 2002-04-09 | アボット・ラボラトリーズ | 共溶媒処方物 |
| JP2011037860A (ja) * | 1998-04-08 | 2011-02-24 | Abbott Lab | 共溶媒処方物 |
| JP2013501790A (ja) * | 2009-08-14 | 2013-01-17 | バーグ バイオシステムズ，エルエルシー | 脱毛症を治療するためのビタミンｄ３およびその類似体 |
| JP2017008064A (ja) * | 2009-08-14 | 2017-01-12 | バーグ エルエルシー | 脱毛症を治療するためのビタミンｄ３およびその類似体 |
| JP2015174854A (ja) * | 2014-03-17 | 2015-10-05 | 学校法人慶應義塾 | まつ毛の成長を伸展するための組成物 |
| WO2016056644A1 (ja) * | 2014-10-09 | 2016-04-14 | 株式会社メディプロデュース | まつ毛用洗浄剤 |
| JP5982070B1 (ja) * | 2014-10-09 | 2016-08-31 | 株式会社メディプロデュース | まつ毛用洗浄剤 |
| CN106999402A (zh) * | 2014-10-09 | 2017-08-01 | 梅迪普罗都司股份有限公司 | 睫毛用清洗剂 |
| US10603266B2 (en) | 2014-10-09 | 2020-03-31 | Mediproduce, Inc. | Eyelash cleaning agent |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0591378B1 (en) | 1999-03-31 |
| CZ289293A3 (en) | 1994-08-17 |
| EP0591378A4 (en) | 1994-03-17 |
| AU667675B2 (en) | 1996-04-04 |
| IE922088A1 (en) | 1992-12-30 |
| DE69228814D1 (de) | 1999-05-06 |
| WO1993000079A1 (en) | 1993-01-07 |
| IL102344A (en) | 1998-01-04 |
| DE69228814T2 (de) | 1999-11-11 |
| IL102344A0 (en) | 1993-01-14 |
| HUT66153A (en) | 1994-09-28 |
| EP0591378A1 (en) | 1994-04-13 |
| PH31673A (en) | 1999-01-18 |
| SK279673B6 (sk) | 1999-02-11 |
| ATE178206T1 (de) | 1999-04-15 |
| CA2112496A1 (en) | 1993-01-07 |
| SK149093A3 (en) | 1994-08-10 |
| CZ280874B6 (cs) | 1996-04-17 |
| TW272128B (en, 2012) | 1996-03-11 |
| PT100638A (pt) | 1993-09-30 |
| PT100638B (pt) | 1999-09-30 |
| AU2240592A (en) | 1993-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6291443B1 (en) | Method of preventing and treating chemotherapy-induced alopecia with vitamin D3 or a derivative or analog or active metabolite thereof. | |
| US6524623B1 (en) | Therapeutic compositions and methods of use thereof | |
| DE60022021T2 (de) | Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion | |
| CN101198362B (zh) | 在癌症化疗和放疗时保护细胞的局部血管收缩剂制品和方法 | |
| US5962505A (en) | Method for treating hot flashes in humans | |
| CN111166760A (zh) | β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用 | |
| AU2018337933A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| JPH06509072A (ja) | 化学療法により誘発される脱毛の予防および治療法 | |
| CN108283620A (zh) | 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法 | |
| US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
| RU2005131868A (ru) | Фармацевтическая композиция, фармацевтическая комбинация (варианты) и способы их применения | |
| US6627663B2 (en) | Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| US12257255B1 (en) | Timolol maleate gel for topical administration | |
| EP1009345A1 (en) | Skin aging and wound treatment using cell migration agents | |
| EP4382104A1 (en) | Dyclonine for use in the topical treatment of hand-foot syndrome | |
| CN120459208A (zh) | 一种用于预防或治疗脱发的组合物 | |
| CN1108537A (zh) | 家庭主妇型皮炎的治疗 | |
| CA3197525A1 (en) | Methods and products including specific cannabinoids | |
| CN119909189A (zh) | 一种用于治疗斑秃的复方制剂 | |
| CN106265112A (zh) | 促进伤口愈合的药物、化妆用组合物和食品添加剂 | |
| KR20240154540A (ko) | 국소 조성물 및 방법 | |
| Camisa | Anthralin | |
| US20040170674A1 (en) | Noninvasive methods for treating hemangiomas | |
| CZ2002729A3 (cs) | Pouľití dexrazoxanu, výrobek obsahující dexrazoxan, způsob léčení lupénky a způsob výroby léku |